Severe autogenously fecal peritonitis in Wistar rats with permanent bilateral carotid occlusion. Response to intra peritoneal moxifloxacin combined with dexamethasone

Acta Cirurgica Brasileira

Volumn 29, Issue 2, 2014, Pages 76-81

  Melo, Maria Cecília Santos Cavalcanti ^a   Gadelha, Diego Nery Benevides ^a   Oliveira, Thárcia Kiara Beserra ^b   Brandt, Carlos Teixeira ^a  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^b FEDERAL UNIVERSITY OF CAMPINA GRANDE   (Brazil)

Author keywords

Dexamethasone; Peritonitis; Quinolones; Rats; Therapy

Indexed keywords

DEXAMETHASONE; MOXIFLOXACIN;

ABDOMINAL ABSCESS; ABDOMINAL WALL DEFECT; ADULT; ANIMAL EUTHANASIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; BRAIN PERFUSION; BREATHING RATE; CAROTID ARTERY OBSTRUCTION; COLONY FORMING UNIT; CONTROLLED STUDY; FECAL PERITONITIS; FOLLOW UP; MORBIDITY; MORTALITY; NONHUMAN; ORCHITIS; PERITONITIS; RAT; SEPSIS; SEPTIC SHOCK; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; CAROTID ARTERY, COMMON; DEXAMETHASONE; DRUG COMBINATIONS; FECES; FLUOROQUINOLONES; MODELS, ANIMAL; PERITONITIS; RATS, WISTAR; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TISSUE ADHESIONS; TREATMENT OUTCOME;

EID: 84895126514     PISSN: 01028650     EISSN: 16782674     Source Type: Journal    
DOI: 10.1590/S0102-86502014000200001     Document Type: Article

References (32)

1. Leibovitz E. The use of fluoroquinolones in children. Curr Opin Pediatr. 2006;18:64-70.
2. Nolwenn Le Saché N, Baud O, Julien Pansiot J, Pham H, Biran V, Nadège Brunel-MeunierN, Philippe Bidet P, Kitzis MD, Gressens P, Bingen E, Stéphane Bonacorsi S. Effect of moxifloxacin combined with cefotaxime compared to cefotaxime-gentamicin combination on prevention of white matter damage associated with Escherichia coli sepsis in neonatal rats. Antimicrob Agents Chemother. 2011;55(7):3567-9.
3. Perdue PW, Kazarian KK, Nevola J, Law WR, Williams T. The use of local and systemic antibiotic in rat fecal peritonitis. J Surg Res. 1994;57:360-5.
4. Ablan CJ, Olen RN, Dobrin PB, ÒKeefe P, Tatarowicz W, Freeark RJ. Efficacy of intraperitoneal antibiotics in treatment of severe fecal peritonitis. Am J Surg. 1991;162:453-6.
5. Vallance S, Waldron R. Antiseptic vs. saline lavage in purulent and faecal peritonitis. J Hosp Infect. 1985;6:87-91.
6. Platt J, Jones RA, Bucknall RA. Intraperitoneal antiseptics in experimental bacterial peritonitis. Br J Surg. 1984;71:626-8.
7. Iakovlev SV, Ramishvili VSh, Nazarov VV, Eremina LV. Efficacy of moxifloxacin in the treatment of secondary peritonitis. Antibiot Khimioter. 2006;51(5):3-10.
8. Sikkink CJ, de Man B, Bleichrodt RP, van Goor H. Auto-cross-linked hyaluronic acid gel does not reduce intra-abdominal adhesions or abscess formation in a rat model of peritonitis. J Surg Res. 2006;136(2):255-9.
9. Carvalho CBGM, Petroianu A, Rodrigues FHOC, Rocha RF. Estudo comparativo entre diversos tipos de tratamento para peritonite fecal em rato. Rev Col Bras Cir. 2002;29(1):43-8.
10. Freitas LL, Soriano E, Muccioli C, Höfling-Lima AL, Belfort Jr R. Efficacy and tolerability of a combined moxifloxacin/dexamethasone formulation for topical prophylaxis and reduction of inflammation in phacoemulsification: a comparative, double masked clinical trial. Curr Med Res Opin. 2007;23(12):3123-30.
11. Espiritu CR, Sy ME, Tayengco TL. Efficacy and tolerability of a combined moxifloxacin/dexamethasone formulation for topical prophylaxis in phacoemulsification: an open-label single-arm clinical trial. J Ophthalmol. 2011;2011:769571.
12. Campos M, Ávila M, Belfort Jr R. Efficacy and tolerability of a fixed-dose moxifloxacin - dexamethasone formulation for topical prophylaxis in LASIK: a comparative, double-masked clinical trial. Clin Ophthalmol. 2008;2(2):331-8.
13. Solomkin J, Zhao YP, Ma EL, Chen MJ, Hampel B; DRAGON Study Team. Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections. Int J Antimicrob Agents. 2009;34(5):439-45.
14. Mu YP, Liu RL, Wang LQ, Deng X, Zhu N, Wei MD, Wang Y. Moxifloxacin monotherapy for treatment of complicated intra-abdominal infections: a meta-analysis of randomized controlled trials. Int J Clin Pract. 2012;66(2):210-7.
15. Uddin MN, Siddiq A, Oettinger CW, D'Souza MJ. Potentiation of pro-inflammatory cytokine suppression and survival by microencapsulated dexamethasone in the treatment of experimental sepsis. J Drug Target. 2011;19(9):752-60.
16. Stass H, Rink AD, Delesen H, Kubitza D, Vestweber KH. Pharmacokinetics and peritoneal penetration of moxifloxacin in peritonitis. J Antimicrob Chemother. 2006;58(3):693-6.
17. Prausnitz MR, Noonan JS. Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J Pharm Sci. 1998;87(12):1479-88.
18. Farkas E, Luiten PG, Bari F. Permanent, bilateral common carotid artery occlusion in the rat: a model for chronic cerebral hypoperfusion-related neurodegenerative diseases. Brain Res Rev. 2007;54:162-80.
19. Otori T, Katsumata T, Katayama Y, Terashi A. Measurement of regional cerebral blood flow and glucose utilization in rat brain under chronic hypoperfusion conditions following bilateral carotid artery occlusion. Analyzed by autoradiographical methods. Nippon Ika Daigaku Zasshi. 1997;64:428-39.
20. Gadelha DNB, Melo MCSC, Oliveira TKB, Brandt CT. Autogenous fecal peritonitis in Wistar rats with permanent bilateral carotid occlusion: morbidity, mortality and microbiological response. Acta Cir Bras. 2013;28(4):299-306.
21. Kayaoǧlu HA, Ozkan N, Yenidoǧan E, Köseoǧlu RD. Effect of antibiotic lavage in adhesion prevention in bacterial peritonitis. UlusTravma Acil Cerrahi Derg. 2013;19(3):189-94.
22. Blot S, De Waele JJ, Vogelaers D. Essentials for selecting antimicrobial therapy for intra-abdominal infections. Drugs. 2012;72 (6):17-32.
23. Shi G, Chen X, Wang H, Wang S, Guo X, Zhang X. Activity of sitafloxacin against extracellular and intracellular Staphylococcus aureus in vitro and in vivo: comparison with levofloxacin and moxifloxacin. J Antibiot (Tokyo). 2012;65(5):229-36.
24. Weiss G, Reimnitz P, Hampel B, Muehlhofer E, Lippert H. AIDA Study Group Moxifloxacin for the treatment of patients with complicated intra-abdominal infections (the AIDA Study). J Chemother. 2009;21(2):170-80.
25. Rink AD, Stass H, Delesen H, Kubitza D, Vestweber KH. Pharmacokinetics and tissue penetration of moxifloxacin in intervention therapy for intra-abdominal abscess. Clin Drug Investig. 2008;28(2):71-9.
26. Cisneros R, Onderdonk AB. Antimicrobial efficacy testing of moxifloxacin during the peritonitis and abscess formation stages of intra-abdominal sepsis: a controlled trial in the rat model. Curr Ther Res. 2002;63(12):821-7.
27. Brunkhorst FM, Oppert M, Marx G, Bloos F, Ludewig K, Putensen C, Nierhaus A, Jaschinski U, Meier-Hellmann A, Weyland A, Gründling M, Moerer O, Riessen R, Seibel A, Ragaller M, Büchler MW, John S, Bach F, Spies C, Reill L, Fritz H, Kiehntopf M, Kuhnt E, Bogatsch H, Engel C, Loeffler M, Kollef MH, Reinhart K, Welte T; German Study Group Competence Network Sepsis (SepNet). Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial. JAMA. 2012;307(22):2390-9.
28. Le Saché N, Baud O, Pansiot J, Pham H, Biran V, Brunel-Meunier N, Bidet P, Kitzis MD, Gressens P, Bingen E, Charriaut-Marlangue C, Bonacorsi S.Effect of moxifloxacin combined with cefotaxime compared to cefotaxime-gentamicin combination on prevention of white matter damage associated with Escherichia coli sepsis in neonatal rats. Antimicrob Agents Chemother. 2011;55(7):3567-9.
29. Li GM, Ji MH, Sun XJ, Zeng QT, Tian M, Fan YX, Li WY, Li N, Yang JJ. Effects of hydrogen-rich saline treatment on polymicrobial sepsis. J Surg Res. 2013;181(2):279-86.
30. Kreimer F, Aguiar JLA, Castro CMMB, Lacerda CM, Reis T, Lisboa Júnior F. Resposta terapêutica e inflamatória de ratos com peritonite secundária submetidos ao uso tópico de ampicilina/sulbactam. Acta Cir Bras. 2005;20(1):31-9.
31. Brocco MC, Paulo DN, Baptista JF, Carraretto AR, Ferrari TA, de Azevedo TC, da Silva AL Effects of peritoneal lavage with bupivacaine on survival of mice with fecal peritonitis. Rev Bras Anestesiol. 2008;58(5):470-9.
32. Brocco MC, Gomez RS, Paulo DN, Almeida CE, Baptista JF. Histological features of peritoneal lavage with ropivacaine in rats with fecal peritonitis. Acta Cir Bras. 2012;27 (2):193-9.